Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05378711 |
Other study ID # |
13-718F |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 2
|
First received |
|
Last updated |
|
Start date |
January 1, 2014 |
Est. completion date |
May 30, 2015 |
Study information
Verified date |
May 2022 |
Source |
Michigan State University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The Department of Counseling, Educational Psychology, and Special Education and the
Department of Psychiatry at Michigan State University have coordinated efforts to provide a
diagnostic and treatment investigation for children, ages seven to eighteen, with Selective
Mutism. The purpose of this study is to examine the utility of fluoxetine for the treatment
of this debilitating disorder. Fluoxetine is expected to improve social anxiety and selective
mutism symptomology.
Description:
Children with selective mutism (SM) are at risk for current and continuing academic and
socio-emotional difficulties. Unfortunately, this issue is complicated by the fact these
children often respond poorly to psychosocial intervention. This leaves parents with the
overwhelming decision to attempt a trial of medication regardless of the little available
data on the evidence base of this approach. Despite the paucity of research, psychiatrists
are prescribing fluoxetine for children with SM "off label", as the Food and Drug
Administration (FDA) has yet to approve fluoxetine for this indication. This study blends the
psychopharmacological expertise of psychiatrists with the mental health, systems, and
psychological evaluation expertise of school psychologists to identify an appropriate
psychopharmacological solution for children and adolescents with this debilitating disorder.
To that end, this study will examine the utility of fluoxetine for the treatment of five
children and adolescents, ages seven to eighteen, diagnosed with SM through the use of a
non-concurrent multiple-baseline single-case design with a single-blind placebo-controlled
procedure. Treatment effectiveness will be evaluated by visual analysis of the data, the
Wampold and Worsham multiple-baseline design randomization test, and the Kendall's Tau +
Mann-Whitney U effect size. Multiple methods of assessment including standardized measures,
such as the Selective Mutism Questionnaire (SMQ), and behavior ratings, such as Direct
Behavior Ratings (DBRs), will be used to gather baseline and treatment data. Multiple
informants (i.e., parents, teachers, and psychiatrists) will provide information on treatment
effect across settings (i.e., school and community). Information regarding adverse effects
associated with fluoxetine treatment including a measure of behavioral disinhibition,
parental acceptance of the fluoxetine intervention, and compliance with taking the medication
will also be gathered.